ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
68 announcements
Zydus Lifesciences completed the acquisition of Assertio Holdings via a cash tender offer. Assertio will become a wholly owned subsidiary, expanding Zydus' global portfolio.
Zydus Lifesciences' subsidiary ZHL secured favorable appellate orders dropping GST demands totaling ₹0.42 Crore. This significantly reduces the company's potential tax liability and penalty exposure.
Zydus Lifesciences received a USFDA Warning Letter regarding its Baddi facility's purified talc technical observations. The company expects no impact on current operations or supplies.
Zydus Lifesciences received US FDA Priority Review for its Saroglitazar NDA. This regulatory milestone accelerates the potential US launch for Primary Biliary Cholangitis treatment.
Zydus Lifesciences increased its share buyback price to ₹1,260 per share for a ₹1,100 Crore total offer. Maximum shares reduced to 87,30,158.
Zydus Lifesciences received US FDA Priority Review for its saroglitazar NDA. The PDUFA target action date is set for November 27, 2026, boosting product pipeline visibility.
Zydus Lifesciences reported the transmission of 10,000 shares within its promoter group. The transaction reflects internal succession planning and does not change aggregate promoter control.
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.
Zydus Lifesciences submitted its Annual Secretarial Compliance Report for FY2026. The report noted a minor technical delay in board meeting intimation resulting in total fines of ₹23,600.
Zydus Lifesciences invested ₹9.02 Crore to complete its subscription in Torrent Urja 25. The company now holds a 22.06% stake in the entity.
Zydus delivered a record-breaking FY26 with 17% revenue growth and peak EBITDA margins of 31.2%, significantly exceeding internal expectations.
Zydus Lifesciences reported FY26 revenues of ₹27,148 Crore and approved a ₹1,100 Crore share buyback. Strong performance across segments supports the multi-year growth outlook.
Zydus Lifesciences reported strong FY26 performance with 16% YoY revenue growth and EBITDA margins expanding to 31.2%. Strategic focus remains on US specialty/rare diseases and domestic chronic therapy leadership.
Zydus Lifesciences declared a final dividend of Re. 1 per share for FY2026. The record date is July 24, 2026, pending shareholder approval.
Zydus Lifesciences re-appointed Dr. Sharvil P. Patel as Managing Director and appointed Mr. Kulin S. Lalbhai as Independent Director. Both roles carry five-year terms.
Zydus Lifesciences approved a ₹1,100 Crore share buyback at ₹1,150 per share. The tender offer targets 95,65,217 shares, representing a significant premium to market price.
Zydus Lifesciences Ltd reported revenue from operations of ₹7,587 Cr (+16.2% YoY) and net profit of ₹1,272 Cr (+8.7% YoY) for Q4 FY26.
Zydus Lifesciences reported consolidated net profit of ₹5,040 Crore for FY26. The board recommended a 100% final dividend of ₹1 per equity share.
Zydus Lifesciences is acquiring Assertio Holdings for approximately ₹1580.8 Crore in cash. The deal establishes an immediate U.S. specialty oncology commercial footprint and infrastructure.
Zydus Lifesciences received an appeal order upholding a ₹1.18 Crore GST demand and penalty. The company intends to file a second appeal before GSTAT.
Zydus Lifesciences will hold a board meeting on May 19, 2026, to consider a share buyback proposal. The trading window remains closed until May 21.
Mr. Apurva S. Diwanji ceased to be an Independent Director at Zydus Lifesciences following his tenure completion. The change was effective from May 12, 2026.
Zydus Lifesciences scheduled a board meeting on May 19, 2026, to approve audited FY26 results and recommend a final dividend. Trading window remains closed until May 21.
Zydus Lifesciences Limited announced the conclusion of a USFDA GMP surveillance inspection at its Ahmedabad Biologics Injectable plant. The inspection ended with seven observations and no data integrity issues. The company intends to work closely with the regulator to address these findings expeditiously.
Zydus Lifesciences' subsidiary, Zydus VTEC Limited, received a GST demand and penalty order totaling ₹1.80 Crore for the period September 2020 to March 2023. The issue pertains to alleged inadmissible Input Tax Credit. The company intends to appeal the order and states there is no material financial impact.
Zydus Lifesciences' subsidiary, Amplitude SAS, has acquired a 100% stake in French medical equipment distributor FBC Medical for ₹7.79 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs in France. The transaction was completed on April 30, 2026.
Zydus Lifesciences' step-down subsidiary, Amplitude SAS, completed the 100% acquisition of French medical equipment distributor Aptitude Orthopedie for ₹4.01 Crore. The move internalizes commercial capabilities in France to reduce long-term selling costs and eliminate third-party commission fees.
Zydus Lifesciences Limited's indirect subsidiary, Amplitude SAS, acquired 100% of French medical equipment distributor FBC Medical for Euro 700,000 (₹7.77 Crore). The acquisition, completed on April 30, 2026, aims to internalize commercial capabilities and reduce long-term distribution costs in France.
Zydus Lifesciences Limited, through its subsidiary Amplitude SAS, acquired 100% of French medical equipment distributor Aptitude Orthopedie for approximately ₹3.99 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs.
Zydus Lifesciences Limited, through its subsidiary Zydus Worldwide DMCC, incorporated a new wholly owned subsidiary named Zara Merger SUB Inc. in the USA on April 24, 2026. The new entity belongs to the pharmaceutical industry. There was no cash consideration for the incorporation.